Apoptin-derived peptide acetate is an anticancer polypeptide with cytotoxic properties. It promotes apoptosis and necrosis in gastric cancer cells by modulating PI3K/AKT/ARNT signaling. Within cells, Apoptin-derived peptide acetate inhibits cancer cell invasion and migration and reduces the expression and phosphorylation of the PI3K subunit p85, thereby further inhibiting the PI3K/AKT pathway involved in gastric cancer progression.

Apoptin-derived peptide acetate is effective in various capacities against cancer cells. At concentrations of 40-100 μg/mL over 24 hours, it reverses cisplatin resistance in SGC-7901/CDDP cells by downregulating ARNT through the inhibition of the PI3K/AKT signaling pathway. At 10-30 μg/mL for 24 hours, it inhibits the migration and invasion of SGC-7901, SGC-7901/CDDP, and MGC-803 cells. When used at concentrations of 30-60 μg/mL for 24 hours, it enhances the sensitivity of SGC-7901/CDDP cells to cisplatin. Additionally, at 10-20 μg/mL over the same duration, it increases the proportion of SGC-7901/CDDP cells in the G2/M phase and induces apoptosis. It also exhibits significant inhibitory effects on gastric cancer cells at concentrations ranging from 10-70 μg/mL, applied for 4 to 24 hours.